1176306-10-7

1176306-10-7 structure

Name: Alamandine
Chemical Name: Angiotensin A (1-7) trifluoroacetate salt
CAS Number: 1176306-10-7
Molecular Formula: C₄₀H₆₂N₁₂O₉
Molecular Weight: 854.995
Catalog: Signaling Pathways GPCR/G Protein Angiotensin Receptor
Create Date: 2021-01-10 10:53:07
Modify Date: 2024-01-11 11:12:00
Alamandine, a member of the renin-angiotensin system (RAS), a vasoactive peptide, is an endogenous ligand of the G protein-coupled receptor MrgD. Alamandine targets to protect the kidney and heart through anti-hypertensive actions[1][2].

Name	Angiotensin A (1-7) trifluoroacetate salt
Synonyms	L-Alanyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-proline L-Proline, L-alanyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-

Description	Alamandine, a member of the renin-angiotensin system (RAS), a vasoactive peptide, is an endogenous ligand of the G protein-coupled receptor MrgD. Alamandine targets to protect the kidney and heart through anti-hypertensive actions[1][2].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Metabolic Enzyme/Protease >> Angiotensin-converting Enzyme (ACE) Signaling Pathways >> GPCR/G Protein >> Angiotensin Receptor
In Vitro	Alamandine is generated by catalysis of Ang A via ACE2 or directly from Angiotensin 1-7 (Ang-(1-7)). Derived from angiotensin II (Ang II) by Ang II-converting enzyme 2 (ACE2), it shows vasodilating (thus protective) properties. Ang (1-7) can be decarboxylated to a peptide called Alamandine. Alamandine is also an endogenous peptide identified in human blood[1]. Alamandine elevates cAMP concentration in primary endothelial and mesangial cells, also suggesting Gs coupling[2]. Alamandine decreases secretion, expression, and blood levels of leptin. Alamandine induced expression of iNOS and plasminogen activator inhibitor-1 (PAI-1) in adipose tissue and isolated adipocytes[2].
In Vivo	Alamandine (0.15 μL/h; administered by mini-osmotic pumps; for 6 weeks) treatment ameliorates hypertension and impaires left ventricle (LV) function in SHRs. Also decreases the mass gains of heart and lung in SHRs, suppresses cardiomyocyte cross-sectional area expansion, and inhibits the mRNA levels of atrial natriuretic peptide and brain natriuretic peptide[3]. Animal Model: Male spontaneously hypertensive rats (SHRs, 50-week-old)[3] Dosage: 0.15 μL/h (~50 μg/kg/day) Administration: Administered by mini-osmotic pumps; for 6 weeks Result: Attenuated hypertension, alleviated cardiac hypertrophy, and improved LV function.
References	[1]. Daniel C Villela, et al. Alamandine: a new member of the angiotensin family. Curr Opin Nephrol Hypertens. 2014 Mar;23(2):130-4. [2]. Johanna Schleifenbaum. Alamandine and Its Receptor MrgD Pair Up to Join the Protective Arm of the Renin-Angiotensin System. Front Med (Lausanne). 2019 Jun 11;6:107. [3]. Chi Liu, et al. Alamandine attenuates hypertension and cardiac hypertrophy in hypertensive rats. Amino Acids. 2018 Aug;50(8):1071-1081.

Density	1.4±0.1 g/cm3
Molecular Formula	C₄₀H₆₂N₁₂O₉
Molecular Weight	854.995
Exact Mass	854.476257
LogP	0.12
Index of Refraction	1.657
Storage condition	-20°C

1158522-08-7	940364-43-2
134104-43-1	131615-57-1
6906-52-1	2228575-42-4
930439-75-1	1018584-77-4
1375289-11-4	849349-65-1